Video

Dr. Mims on Developed Mutations in AML

Alice S. Mims, MD, discusses developed resistance in acute myeloid leukemia.

Alice S. Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center—James, discusses developed resistance in acute myeloid leukemia (AML).

With a lot still unknown about resistance in AML, the most is known about patients with IDH1/2 and FLT3 mutations, explains Mims. Patients with IDH1/2-mutated AML often have other mutations, such as RAS and FLT3 mutations. This patient population may not respond well to IDH1/2 inhibitors alone, which is being explored through research regarding whether there are better combination therapies that can be used upfront, says Mims.

Some patients develop resistance mutations after being treated with IDH1/2 inhibitors. For example, a patient may start with an IDH1 mutation and develop an IDH2 mutation. When patients stop responding to treatment that has previously been effective, it is important to repeat molecular profiling to see if patients have acquired new mutations, concludes Mims.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity